How efficacious is SHINGRIX?
SHINGRIX demonstrated >90% efficacy against shingles in adults 50 years of age and older based on pooled data from two large, phase 3 randomised controlled trials.2,3,4,5
Internet Explorer is no longer supported.
To provide you with the best possible experience, please switch to a supported browser e.g.
has been added to your basket
Hear more about the impact of shingles, from real patients like DeAnn.
Help to protect against shingles for patients like DeAnn.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441
SHINGRIX is owned by or licensed to the GSK group of companies.
© 2022 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.
October 2022 | PM-GB-SGX-WCNT-220011 (V3.0)